Pius S. Hornstein – Country Chair, Sanofi China
Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in…
Address:
Tel:
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Through the acquisition of Genzyme, Sanofi has strongly reinforced its footprint in rare diseases.
Diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in…
Pierre Faury, co-President of the French Healthcare Alliance in China as well as vice-President of Sanofi China in charge of Commercial Excellence, shares the mandate of the French Healthcare Alliance…
Among Big Pharma, Sanofi has a track record of placing a lot of faith in emerging markets – with local production, a large product portfolio, and decades of experience. As…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China,…
John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With…
A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s…
In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the…
Vaccinating the elderly has been a key factor in ensuring protection against fatality during COVID-19, writes Bridge Consulting’s Stefania Jiang. However, the experience of it in China has been one…
A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric…
One of China’s leading vaccine manufacturers, CanSino Biologics has taken massive strides since its foundation in 2009 and has secured approvals in several countries for its ebola, meningitis, and COVID-19…
A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial…
See our Cookie Privacy Policy Here
